EQS-News

Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Conference/Study results Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS) 03.05.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding to marketed antipsychotics

International TRS advisory committee will contribute to design of potentially pivotal, multinational, randomized, placebo-controlled trial with evenamide in patients with TRS

A total of six posters will be presented at the upcoming conferences, including:

• Results from all 161 patients at the 6-week primary endpoint of Study 014
• Full data from the one-year interim timepoint from the cohort of the first 100 patients in study 014/015
• Evidence for sustained multidimensional benefits in patients with TRS by combining evenamide’s glutamate release modification with dopamine/serotonin inhibition of current antipsychotics
• Characteristics of early and late responders in patients with treatment-resistant schizophrenia  

Milan, Italy, May 3, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34^th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.